Apogee Therapeutics Inc (NASDAQ: APGE) is 8.63% higher on its value in year-to-date trading and has touched a low of $27.05 and a high of $72.29 in the current 52-week trading range. The question becomes, what are the chances the stock will continue to grow shareholders’ wealth in the market. Here’s what analysts think will happen to its price in the coming time. The APGE stock was last observed hovering at around $49.57 in the last trading session, with the day’s loss setting it -0.36%.
Currently trading at $49.21, the stock is 4.65% and -0.22% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 0.45 million and changing -0.73% at the moment leaves the stock -0.54% off its SMA200. APGE registered 66.59% gain for a year compared to 6-month gain of 16.64%. The firm has a 50-day simple moving average (SMA 50) of $49.4007 and a 200-day simple moving average (SMA200) of $49.574524.
The stock witnessed a -1.52% loss in the last 1 month and extending the period to 3 months gives it a -12.30%, and is 8.63% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 4.69% over the week and 6.34% over the month.
Distance from 52-week low is 81.92% and -31.93% from its 52-week high. The company has generated returns on investments over the last 12 months (-19.72%).
The EPS is expected to grow by 7.87% this year
214.0 institutions hold shares in Apogee Therapeutics Inc (APGE), with institutional investors hold 144.15% of the company’s shares. The shares outstanding are 45.02M, and float is at 36.30M with Short Float at 21.96%. Institutions hold 127.29% of the Float.
Apogee Therapeutics Inc (APGE) Insider Activity
Apogee Therapeutics Inc disclosed in a document filed with the SEC on Jan 02 ’25 that Dambkowski Carl (Chief Medical Officer) sold a total of 4,085 shares of the company’s common stock. The trade occurred on Jan 02 ’25 and was made at $46.94 per share for $0.19 million. Following the transaction, the insider now directly holds 0.26 million shares of the APGE stock.
Still, SEC filings show that on Dec 12 ’24, McKenna Mark C. (Director) acquired 20,000 shares at an average price of $49.54 for $0.99 million. The insider now directly holds 20,000 shares of Apogee Therapeutics Inc (APGE).
